Leap Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 54
- Market Cap
- $113.2M
- Website
- http://www.leaptx.com
Phase 2 Study of DKN-01 in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05480306
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists & Research Institute (FCS), Cape Coral, Florida, United States
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Leap Therapeutics, Inc.
- Registration Number
- NCT04681248
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Cedars Sinai Medical Care Foundation, Los Angeles, California, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT04363801
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03861403
- Locations
- 🇺🇸
Horizon Oncology Research, Lafayette, Indiana, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
- Conditions
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT03395080
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT02628574
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
🇺🇸University Hospitals, Cleveland, Ohio, United States
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02375880
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT02013154
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸CTRC @ The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01711671
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01457417
- Locations
- 🇺🇸
New York Oncology Hematology, P.C., Albany, New York, United States
🇺🇸Texas Oncology - Tyler, Tyler, Texas, United States
🇺🇸Texas Oncology - Baylor, Charles A. Sammonds Cancer Center, Dallas, Texas, United States